Overview

Rituximab in the Treatment of Patients With Bullous Pemphigoid

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Duke University
Collaborator:
Genentech, Inc.
Treatments:
Rituximab